A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
Enrolling By Invitation
99 years or below
All
10 participants needed
1 Location
Brief description of study
This is a multicenter study to evaluate the long-term safety and
tolerability of mavacamten in participants with nHCM who completed
MAVERICK-HCM through Week 24 and enroll into this study within
3 months. All participants will receive active study drug as described
below, but their status (active or placebo) in the original
MAVERICK-HCM study will remain blinded as the studies will be
enrolling in parallel. Approximately 60 participants will be enrolled;
enrollment must occur within 3 months of the participant completing
MAVERICK-HCM.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ['Hypertrophic Cardiomyopathy', 'Obstructive Hypertrophic Cardiomyopathy', 'Non-obstructive Hypertrophic Cardiomyopathy']
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 831510
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
